Journal of Antimicrobial Chemotherapy (1999) 43, 157-158
© 1999 The British Society for Antimicrobial Chemotherapy
Correspondence |
Extended-spectrum ß-lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France
J Antimicrob Chemother 1999; 43: 157–158
a Department of Microbiology, Hôpital de Bicêtre, 78 rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France; b Intensive Care Unit, Hôpital de Bicêtre, 78 rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France; c Department of Infectious Diseases and Clinical Microbiology, Kocaeli University Medical School, 41900 Kocaeli, Turkey
Sir,
Acinetobacter spp., especially Acinetobacter baumannii, are common opportunistic pathogens in immunocompromised patients and currently cause 10% of nosocomial infections in intensive care unit patients. 1 They tend to be resistant to multiple antibiotics and to produce cephalosporinases. 2 Indeed, hyperproduction of cephalosporinases, together with decreased outer membrane permeability, are the predominant mechanisms of resistance to ceftazidime amongst A. baumannii isolates.
Most extended-spectrum ß-lactamases (ESBLs) are the result of mutations that alter the hydrolytic properties of the restricted spectrum penicillinases, TEM-1 and -2 and SHV-1. 3 These enzymes are principally mediated by plasmids which spread readily amongst Enterobacteriaceae and their presence is detected by the demonstration of synergy between clavulanic acid, which inhibits the ß-lactamase, and a third-generation cephalosporin (most effectively ceftazidime) with the double-disc diffusion test.
In the course of routinely assessing all ceftazidime-resistant Acinetobacter spp. isolates by the double-disc diffusion test, we identified a strain of A. baumannii (Ama-1) exhibiting only slight synergy that was most evident when the ceftazidime disc was placed 2 cm from the clavulanic acid disc. The MICs of amoxycillin, ticarcillin, piperacillin, ceftazidime and imipenem for the isolate were determined by the agar dilution method according to recommendations of a working party of the British Society for Antimicrobial Chemotherapy. 4 Ama-1 was resistant to all of the ß-lactams tested, with the exception of imipenem. In the presence of clavulanic acid at a fixed concentration of 2 mg/L, the MIC of ticarcillin was reduced from 512 mg/L to 256 mg/L and that of ceftazidime from 512 mg/L to 128 mg/L. Similarly, in the presence of sulbactam at a concentration of 4 mg/L, the MIC of ceftazidime fell from 512 mg/L to 256 mg/L. The activity of any ß-lactamase(s) produced by this isolate is therefore inhibited only minimally by either ß-lactamase inhibitor. In an attempt to determine the molecular basis of this resistance phenotype, we assayed for a putative ESBL gene by PCR analysis with TEM-specific primers (5'-GTATGGATCCTCAACATTTCCGTGTCG-3' and 5'-ACCAAAGCTTAATCAGTGAGGCA-3') and SHV-specific primers (5'9-TTATCTCCCTGTTAGCCACC-3' and 5'-GATTTGCTGATTTCGCCG-3'). Neither gene was demonstrated. However, primers used to detect the gene for the ESBL, PER-1 (5'-ATGAATGTCATTATAAAAGC-3' and 5'-AATTTGGGCTTAGGGCAGAA-3'), yielded a 925 bp PCR product. 5 The sequence analysis of this product revealed total identity with blaPER-1 which was originally detected in a strain of Pseudomonas aeruginosa. 5
A survey recently carried out in Turkey showed that 46% of Acinetobacter spp. hospital isolates possessed PER-1-type ß-lactamases. 6 In this study, attempts to demonstrate plasmid carriage of blaPER-1 in Ama-1 and to transfer the ESBL resistance phenotype from Ama-1 to Escherichia coli DH10B by mating-out assays and by electroporation (electrotransformation) were unsuccessful.
Ama-1 was isolated following culture of a rectal swab obtained from a 90 year old female patient on the intensive care unit. She had previously been admitted to two other hospitals in Paris but, to the best of our knowledge, had not travelled to Turkey, nor had she been in contact with either Turkish patients or travellers to Turkey. PER-1-positive A. baumannii strains were not isolated from the rectal swabs of 16 other patients on the intensive care unit at the same time as the patient from whom Ama-1 was recovered. Moreover, comparison of ApaI-digested genomic DNA 7 extracted from Ama-1 with DNA from four randomly selected PER-1-type ß-lactamase-positive and one PER- 1-type ß-lactamase-negative A. baumannii strains from Turkey by pulsed-field gel electrophoresis (PFGE) revealed different restriction patterns (Figure). Thus, the French isolate was not clonally related to the Turkish strains.
|
This is the first report from outside Turkey of the detection of an ESBL in an Acinetobacter spp. clinical isolate. We believe that it is also the first description of the sequencing-based identification of an ESBL gene in an Acinetobacter spp. strain. ESBLs such as blaPER-1 may increase the level of naturally occurring multidrug resistance amongst isolates belonging to these species. Strains of Acinetobacter spp. should therefore be included in screening programmes designed to detect ESBL-producing aerobic Gram-negative bacilli as hospital outbreaks caused by these bacteria are common. 7 However, routine detection of such strains may be difficult because the synergy between third-generation cephalosporins and clavulanic acid, typically observed with ESBL-producing Enterobacteriaceae, tends to be minimal with Acinetobacter spp.
Acknowledgments
This work was supported by a grant from the National Education and Research Department, France.
Notes
* Corresponding author. Tel: 133-1-45-21-36-32; Fax:
133-1-45-21-63-40. 
References
1 . Jarlier, V., Fosse, T. & Philippon, A. (1996). Antibiotic susceptibility in aerobic Gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Medicine 22, 1057–65.[ISI][Medline]
2 . Perilli, M., Felici, A., Oratore, A., Cornaglia, G., Bonfiglio, G., Rossolini, G. M. et al. (1996). Characterization of the chromosomal cephalosporinases produced by Acinetobacter iwoffii and Acinetobacter baumannii clinical isolates. Antimicrobial Agents and Chemotherapy 40, 715–9.[Abstract]
3 . Philippon, A., Arlet, G. & Lagrange, P. H. (1994). Origin and impact of plasmid-mediated extended-spectrum ß-lactamases. European Journal of Clinical Microbiology and Infectious Diseases 13, Suppl. 1, S17–29.
4
.
Working Party of the British Society for Antimicrobial Chemotherapy. (1991). A
guide to
sensitivity testing. Journal of Antimicrobial Chemotherapy 27, Suppl. D,1
–50.
5
.
Nordmann, P. & Naas, T. (1994). Sequence analysis of PER-1 extended-spectrum
ß-lactamase from Pseudomonas aeruginosa and comparison with class A
ß-lactamases. Antimicrobial Agents and Chemotherapy 38, 104–14.
6 . Vahaboglu, H., Ozturk, R., Aygun, G., Coskunkan, F., Yaman, A., Kaygusuz, A. et al. (1997). Widespread detection of PER-1-type extended-spectrum ß-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrobial Agents and Chemotherapy 41,2265 –9.[Abstract]
7
.
Tankovic, J., Legrand, P., De Gatines, G., Chemineau, V., Brun-Buisson, C. & Duval, J.(1994).
Characterization of a hospital outbreak of imipenem-resistant Acinetobacter
baumannii by phenotypic and genotypic typing methods. Journal of Clinical
Microbiology 32, 2677–81.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Y. Peleg, H. Seifert, and D. L. Paterson Acinetobacter baumannii: Emergence of a Successful Pathogen Clin. Microbiol. Rev., July 1, 2008; 21(3): 538 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Empel, K. Filczak, A. Mrowka, W. Hryniewicz, D. M. Livermore, and M. Gniadkowski Outbreak of Pseudomonas aeruginosa Infections with PER-1 Extended-Spectrum {beta}-Lactamase in Warsaw, Poland: Further Evidence for an International Clonal Complex J. Clin. Microbiol., September 1, 2007; 45(9): 2829 - 2834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Power, J. Di Conza, M. M. Rodriguez, B. Ghiglione, J. A. Ayala, J. M. Casellas, M. Radice, and G. Gutkind Biochemical Characterization of PER-2 and Genetic Environment of blaPER-2 Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2359 - 2365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Endimiani, F. Luzzaro, R. Migliavacca, E. Mantengoli, A. M. Hujer, K. M. Hujer, L. Pagani, R. A. Bonomo, G. M. Rossolini, and A. Toniolo Spread in an Italian Hospital of a Clonal Acinetobacter baumannii Strain Producing the TEM-92 Extended-Spectrum {beta}-Lactamase Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2211 - 2214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Naas, P. Bogaerts, C. Bauraing, Y. Degheldre, Y. Glupczynski, and P. Nordmann Emergence of PER and VEB extended-spectrum {beta}-lactamases in Acinetobacter baumannii in Belgium J. Antimicrob. Chemother., July 1, 2006; 58(1): 178 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heritier, L. Poirel, P.-E. Fournier, J.-M. Claverie, D. Raoult, and P. Nordmann Characterization of the Naturally Occurring Oxacillinase of Acinetobacter baumannii Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4174 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Handal, C. Giraud-Morin, D. A. Caugant, I. Madinier, I. Olsen, and T. Fosse Chromosome- and Plasmid-Encoded {beta}-Lactamases in Capnocytophaga spp. Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3940 - 3943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Hujer, N. S. Hamza, A. M. Hujer, F. Perez, M. S. Helfand, C. R. Bethel, J. M. Thomson, V. E. Anderson, M. Barlow, L. B. Rice, et al. Identification of a New Allelic Variant of the Acinetobacter baumannii Cephalosporinase, ADC-7 {beta}-Lactamase: Defining a Unique Family of Class C Enzymes Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2941 - 2948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Poirel, L. Cabanne, H. Vahaboglu, and P. Nordmann Genetic Environment and Expression of the Extended-Spectrum {beta}-Lactamase blaPER-1 Gene in Gram-Negative Bacteria Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1708 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sturenburg, M. Lang, M. A. Horstkotte, R. Laufs, and D. Mack Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum {beta}-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria J. Antimicrob. Chemother., November 1, 2004; 54(5): 870 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nagano, Y. Nagano, C. Cordevant, N. Shibata, and Y. Arakawa Nosocomial Transmission of CTX-M-2 {beta}-Lactamase-Producing Acinetobacter baumannii in a Neurosurgery Ward J. Clin. Microbiol., September 1, 2004; 42(9): 3978 - 3984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jain and L. H Danziger Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians Ann. Pharmacother., September 1, 2004; 38(9): 1449 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Joshi, G. M. Litake, V. S. Ghole, and K. B. Niphadkar Plasmid-borne extended-spectrum {beta}-lactamase in a clinical isolate of Acinetobacter baumannii J. Med. Microbiol., December 1, 2003; 52(12): 1125 - 1127. [Full Text] [PDF]
|
|
|
|
|
|
L. Poirel, O. Menuteau, N. Agoli, C. Cattoen, and P. Nordmann Outbreak of Extended-Spectrum {beta}-Lactamase VEB-1-Producing Isolates of Acinetobacter baumannii in a French Hospital J. Clin. Microbiol., August 1, 2003; 41(8): 3542 - 3547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yong, J. H. Shin, S. Kim, Y. Lim, J. H. Yum, K. Lee, Y. Chong, and A. Bauernfeind High Prevalence of PER-1 Extended-Spectrum {beta}-Lactamase-Producing Acinetobacter spp. in Korea Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1749 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-W. Chu, M. Afzal-Shah, E. T. S. Houang, M.-F. I. Palepou, D. J. Lyon, N. Woodford, and D. M. Livermore IMP-4, a Novel Metallo-{beta}-Lactamase from Nosocomial Acinetobacter spp. Collected in Hong Kong between 1994 and 1998 Antimicrob. Agents Chemother., March 1, 2001; 45(3): 710 - 714. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Tranier, A.-T. Bouthors, L. Maveyraud, V. Guillet, W. Sougakoff, and J.-P. Samama The High Resolution Crystal Structure for Class A beta -Lactamase PER-1 Reveals the Bases for Its Increase in Breadth of Activity J. Biol. Chem., September 1, 2000; 275(36): 28075 - 28082. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||